2. Summary of stage and residual disease in included interval debulking surgery (IDS) studies.
| Study | No. | Stage | Optimal | Suboptimal | Median follow‐up | Median age in years | Setting | |
| III n (%) | IV n (%) | n (%) | n (%) | Months | (Range) | |||
| Cioffi 2018 | 102 | 64 (63) | 38 (37) | 0: 37 (44) < 1: 20 (23)† |
≥ 1: 28 (33)† | Not reported | Mean age ≥ 70 years: 74.5 (41%) < 70 years: 58.3 (59%) |
Italy |
| Davidson 2019 | 282 | IIIC: 114 (40) IV: 101 (36) Assumed AOC: 57 (20) Unknown: 10 (4) |
0: 165 (59)‡ ≤ 1: 63 (22)‡ |
> 1 to 2: 6 (2)‡ > 2: 37 (13)‡ |
Not reported | 63.9 (34.1 to 84.8) | USA | |
| Iwase 2015 | 124 | IIIB: 6 (5) IIIC: 77 (62) |
41 (33) | < 1: 113 (91) | ≥ 1: 11 (9) | 39.5 (5 to 142) | 58 (29 to 83) | Japan |
| Kaban 2017 | 203 | Not reported | ≤ 1: 165 (81)§ | > 1: 36 (19)§ | 34.5 (1 to 124) | 59 (28 to 84) | Turkey | |
| Lecuru 2019 | 188 | Not reported | Not reported | 42.6 | Not reported | France | ||
| Lorusso 2016 | 193 | Not reported | Not reported | Not reported | Not reported | Italy | ||
| Petrillo 2014 | 322 | 251 (78) | 72 (22) | No definition of optimal given 0: 236 (73) ≤ 1: 36 (11) > 1: 50 (16) |
47 (3 to 181) | ≤ 65: 226 (70%) > 65: 96 (30%) |
Italy | |
| Phillips 2018 | 398 | 273 (69) | 123 (31) | 0: 255 (64) < 1: 55 (14) |
≥ 1: 88 (22) | Not reported | Mean: 63.9 (95% CI 42.2 to 85.6) |
UK |
| Stoeckle 2014 | 118 | 82 (69) | 36 (31) | 0: 80 (68) < 1: 31 (26) |
≥ 1: 7 (6) | 37 | 64 (37 to 88) | France |
| Zhang 2018 | 200 | 169 (85) | 31 (15) | 0: 59 (30) < 1: 38 (19) |
1 to 2: 8 (4) > 2: 30 (15) |
43.5 (IQR 38.5 to 56.2) | 61 (38 to 80) | China |
| Zhu 2016 | 672 | 564 (84) | 108 (16) | ≤ 1: 486 (72) | > 1: 186 (28) | 38 (5 to 103) | 55 (30 to 70) | China |
†85/102 participants underwent debulking surgery following neoadjuvant chemotherapy.
‡Residual disease data available for n = 271/282.
§Residual disease data available for n = 201/203.
AOC: advanced ovarian cancer; CI: confidence interval; IQR: interquartile range